Twist Bioscience Corp
🔔 Watch stock
Assessment
Our Rating
A journalistic assessment by our editorial team at the time of the deep dive — it rates the company, not the entry point. Not investment advice and not a solicitation to buy or sell.
The business works in principle, but one material question is open. As long as it stays open, our findings do not carry a quality verdict.
Why this colour
The business works, the balance sheet carries no debt and the gross margin demonstrably climbed from 36.6 to 50.7 percent — there is no substance finding that threatens the company itself: no going concern warning, no negative equity, no interest burden. What remains open is the decisive operating question, and after twelve years it is still open: whether this revenue ever turns into profit. As long as selling and administration cost more than gross profit delivers, and the only progress on the loss line comes from a one-time sale, the turnaround is unproven — that is yellow, not green. Our view that the stock is expensive at 13 times revenue does not change the colour: price is not a quality attribute. The decision is yours.
What the thesis turns on
Assessment: Opportunities & Risks
Twist Bioscience has a technically convincing product, a gross margin that has risen for three straight years and a debt-free balance sheet — but not yet a business model that turns 20 percent growth into profit: selling and administrative expenses alone cost more in fiscal 2025 than the entire gross profit delivered, and the seemingly halved loss owes itself to a one-time sale. Not investment advice.
Product and market position
The core business works: fiscal 2025 revenue of $376.6 million, up 20 percent, 938,000 genes shipped, up 22 percent, more than 3,800 customers and 99 percent of revenue from repeat customers. In the quarter ended March 31, 2026 revenue grew 19.3 percent to $110.7 million and genes shipped rose 32 percent.
Gross margin
Manufacturing is measurably improving: gross margin of 36.6 percent in fiscal 2023, 42.6 percent in 2024, 50.7 percent in 2025 and 51.8 percent for the half year ended March 31, 2026 — with production fixed costs held broadly flat. This is the strongest evidence that the silicon-chip process scales.
Cost structure
Selling and administrative expenses exceed gross profit: $247.0 million against $191.0 million in fiscal 2025, and $76.1 million against $57.1 million in the quarter ended March 31, 2026. In that same quarter gross profit rose $11.1 million while selling and administrative expenses rose $12.4 million. The relief management has guided to for the second half of fiscal 2026 is still unproven.
Quality of earnings
The fall in net loss from $208.7 million in fiscal 2024 to $77.7 million in fiscal 2025 rests on a $48.8 million book gain from the May 2, 2025 sale of the data storage unit. Without that item the loss was about $126.5 million. In the half year ended March 31, 2026 the loss rose again to $74.5 million from $70.9 million.
Balance sheet and funding
No meaningful financial debt (debt-to-equity 0.03), equity of $455.1 million and $171.7 million of cash and short-term investments as of March 31, 2026 — set against roughly $30 million of cash outflow per quarter and an at-the-market program of up to $200 million available since June 18, 2026.
Valuation
About $5.62 billion of market value (data as of July 26, 2026) stands against $409.5 million of annual revenue and $359.9 million of tangible book value — roughly 13 times revenue and 15 times tangible substance, without earnings. The price assumes the cost curve breaks before the cash does.
Worth Noting
Origin: our in-house stock scanner, list "Richard Moglen: 1 Week Top Performers" (U.S. selection), rank 12 of 28 hits, RS rating 96, as of July 25, 2026. The list is recalculated daily.
Data as of: SEC filings through the Form 10-Q for the quarter ended March 31, 2026 (filed May 4, 2026) plus the Form S-3ASR of June 18, 2026; market data as of July 26, 2026 (closing price July 24, 2026). The next quarterly report, for the quarter ended June 30, 2026, was not available at the time of writing.
Easily confused: the DNA data storage business has not belonged to Twist since May 2, 2025 — it is now the standalone Atlas Data Storage, Inc., in which Twist holds only a minority stake. The earlier patent dispute with Agilent Technologies has been settled; the fiscal 2025 annual report lists Agilent only as a competitor.
Stock Watch
This analysis is as of August 26, 2026. Stock Watch will tell you what's changed at TWST since then.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 25.50 $ to 155.60 $ · Last price: 155.60 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Diagnostics & Research
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Twist Bioscience Corp TWST | 9.7 | – | -35.3 | 52.0 | -34.9 | 20.3 | 476.8 |
| Thermo Fisher Scientific Inc TMO | 241.9 | 36.8 | 21.9 | 41.0 | 17.9 | 3.9 | 39.8 |
| Danaher Corporation DHR | 150.1 | 41.8 | 21.5 | 58.8 | 22.9 | 2.9 | 11.0 |
| Natera Inc NTRA | 52.8 | – | -26.8 | 65.2 | -12.4 | 35.9 | 97.3 |
| IQVIA Holdings Inc IQV | 45.2 | 33.9 | 16.6 | 33.0 | 13.6 | 5.9 | 43.9 |
| Agilent Technologies Inc A | 44.2 | 31.0 | 21.4 | 53.7 | 23.7 | 6.7 | 21.8 |
| Waters Corporation WAT | 42.2 | 53.4 | 46.7 | 56.3 | 2.8 | 7.0 | 38.1 |
| IDEXX Laboratories Inc IDXX | 40.3 | 37.7 | 25.4 | 62.5 | 31.8 | 10.4 | -20.5 |
| Illumina Inc ILMN | 37.1 | 43.7 | 23.7 | 67.9 | 18.3 | -0.8 | 143.1 |
| Median of companies shown | 44.2 | 37.7 | 21.5 | 56.3 | 17.9 | 6.7 | 39.8 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 2 | -44 | -44 | -2.35 | -39 | -77 | 76 |
| 2017 | 11 | -58 | -59 | -3.16 | -51 | -133 | 86 |
| 2018 | 25 | -71 | -71 | -2.68 | -66 | -201 | 116 |
| 2019 | 54 | -109 | -108 | -3.92 | -88 | 152 | 187 |
| 2020 | 90 | -140 | -140 | -3.57 | -142 | 336 | 399 |
| 2021 | 132 | -153 | -152 | -3.15 | -112 | 581 | 702 |
| 2022 | 204 | -249 | -218 | -4.04 | -124 | 789 | 961 |
| 2023 | 245 | -217 | -205 | -3.60 | -142 | 623 | 776 |
| 2024 | 313 | -221 | -209 | -3.60 | -64 | 473 | 614 |
| 2025 | 377 | -136 | -78 | -1.30 | -48 | 473 | 642 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.53 | – | 89 | 24.10 | -35.60 | -21 | -24 |
| 2025: Q1 | -0.66 | – | 93 | 23.20 | -42.40 | -13 | -17 |
| 2025: Q2 | 0.33 | – | 96 | 17.90 | 21.20 | -1 | -11 |
| 2025: Q3 | -0.45 | – | 99 | 16.90 | -27.40 | -12 | -24 |
| 2025: Q4 | -0.50 | – | 104 | 16.90 | -29.40 | -25 | -35 |
| 2026: Q1 | -0.71 | – | 111 | 19.30 | -39.80 | -18 | -26 |
| 2026: Q2 | -0.56 | -269.70 | 118 | 23.20 | -29.60 | 1 | -9 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 27 of our scanner strategies — each hit links to the scanner.
Growth
Quality & Balance Sheet
Breakout & Setup
Momentum & Trend
- 21-EMA Trend
- Above the 50- & 200-SMA
- Gary Antonacci: Dual Momentum (Stock Adaptation)
- High ADR (≥5%)
- Kathy Donnelly: Liquid Movers Up
- Mark Minervini: Trend Criteria — 1 Month
- Mike Webster: Power Trend Leader
- Mike Webster: Swing Trading List
- Near 52-Week High
- Oliver Kell: Doublers
- Oliver Kell: Strength on Down Day
- Qullamaggie: Top Gainers 1M
- Qullamaggie: Trend Intensity (13/65)
- RS Leader (≥90)
- RS New Highs
- Richard Moglen: 1 Week Top Performers
- Richard Moglen: Top Performers 3/6 Month
- Stage 2 Leader
- Stan Weinstein: Checklist
- Stan Weinstein: Stage 2
Research
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 09/30/2026 | -0.60 | -0.63 – -0.57 | 456 | 71.6% | 3 |
| 09/30/2027 | -0.63 | -2.05 – 0.10 | 540 | -5.4% | 4 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Twist verkauft keine KI-Produkte, sondern synthetische DNA — und benennt im Geschäftsbericht 2025 ausdrücklich, dass KI die Nachfrage nach bestimmten Formen der Gensynthese senken und die Branche umwälzen könnte; intern wird KI nur zur Effizienzsteigerung eingesetzt.
View the full file — quotes, sources, reviewed filings
„Further, while the impact that AI may have on the synthetic biology industry is still uncertain, recent advances in AI capabilities may indicate that it could be a significant disruptor in the synthetic biology industry. For example, AI may reduce customer demand for certain types of gene synthesis."
Zudem könnten die jüngsten Fortschritte bei den KI-Fähigkeiten darauf hindeuten, dass KI ein erheblicher Umwälzungsfaktor in der Branche der synthetischen Biologie sein könnte — auch wenn die Auswirkungen von KI auf diese Branche noch ungewiss sind. Zum Beispiel könnte KI die Kundennachfrage nach bestimmten Formen der Gensynthese verringern.
10-K · 2025-11-17 · View SEC filing
„In our ongoing efforts to innovate and optimize operational efficiency, we have integrated AI and machine learning into various aspects of our workplace. While AI and machine learning presents opportunities for enhanced productivity and innovation, it also introduces inherent risks, including legal and regulatory compliance risks and potential liability, that could adversely impact our business and reputation."
In unserem fortlaufenden Bemühen, Innovation und betriebliche Effizienz zu steigern, haben wir KI und maschinelles Lernen in verschiedene Bereiche unseres Arbeitsalltags eingebunden. KI und maschinelles Lernen eröffnen zwar Chancen für höhere Produktivität und Innovation, bringen aber auch immanente Risiken mit sich — darunter Risiken der Rechts- und Regulierungskonformität sowie mögliche Haftung —, die unserem Geschäft und unserem Ruf schaden könnten.
10-K · 2025-11-17 · View SEC filing
„Customers pursuing artificial intelligence (“AI”) enabled antibody discovery platforms may use Twist to generate not only the antibodies of interest but also comprehensive high quality characterization data that is critical for use in the development and refinement of algorithms and subsequently used for the identification of therapeutic antibody candidates with appropriate developability properties."
Kunden, die auf künstlicher Intelligenz („KI“) beruhende Plattformen zur Antikörper-Entdeckung verfolgen, können Twist nutzen, um nicht nur die gewünschten Antikörper zu erzeugen, sondern auch umfassende, hochwertige Charakterisierungsdaten, die für die Entwicklung und Verfeinerung von Algorithmen entscheidend sind und anschließend zur Identifizierung therapeutischer Antikörper-Kandidaten mit geeigneten Entwicklungseigenschaften verwendet werden.
10-K · 2025-11-17 · View SEC filing
Filings Reviewed: 10-Q 2026-05-04 · 10-Q 2026-02-02 · 10-K 2025-11-17 · 10-Q 2025-08-04 · 10-Q 2025-05-05 · 10-K 2024-11-18
Rated on July 26, 2026 · How the Rating Is Built
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 22.8%
- More than 10% revenue growth is expected for the coming year 16.1%
- Share count grows by less than 3% a year 3.5%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 0.2%
- Gross margin at 40% or higher and without meaningful erosion 50.7%
- Goodwill from acquisitions does not grow faster than revenue 12.8%
- Net debt below twice EBITDA 95 m net cash
- Operating cash flow covers the profits of the last three years 237 m
- Return on capital at 15% or higher, or up versus two years ago -24.8%
- Insiders hold at least 10% or are net buyers 1.3%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
5/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 76.5%
- Exp. sales growth 3Y > 5% 19.7%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 19.7%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -20.6%
- ROCE > 15% -24.8%
- Expected return > 10% 18.8%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | Cho Dennis | See Remarks | Sell | 412 | 122.62 | 50,521 |
| Sep 8, 2026 | Green Paula | SVP of Human Resources | Sell | 907 | 122.62 | 111,220 |
| Sep 8, 2026 | Leproust Emily M. | Chief Executive Officer | Sell | 2,302 | 122.62 | 282,280 |
| Sep 8, 2026 | Werner Robert F. | Chief Accounting Officer | Sell | 238 | 122.62 | 29,185 |
| Aug 25, 2026 | Leproust Emily M. | Chief Executive Officer | Sell | 1,093 | 154.45 | 168,809 |
| Aug 25, 2026 | Leproust Emily M. | Chief Executive Officer | Sell | 9,181 | 153.93 | 1,413,204 |
| Aug 25, 2026 | Leproust Emily M. | Chief Executive Officer | Sell | 6,412 | 152.75 | 979,433 |
| Aug 25, 2026 | Leproust Emily M. | Chief Executive Officer | Sell | 12,236 | 151.36 | 1,851,980 |
| Aug 25, 2026 | Leproust Emily M. | Chief Executive Officer | Sell | 12,648 | 150.56 | 1,904,333 |
| Aug 24, 2026 | Werner Robert F. | Chief Accounting Officer | Sell | 854 | 140.77 | 120,220 |
The company
About the Company
Twist Bioscience Corporation fertigt und verkauft synthetische DNA-basierte Produkte. Das Unternehmen bietet synthetische Gene und Genfragmente für die Produktentwicklung in den Bereichen Therapeutika, Diagnostik, Chemikalien/Materialien, Lebensmittel/Landwirtschaft, Datenspeicherung und verschiedene Anwendungen in der akademischen Forschung…
- Employees
- 979
- Headquarters
- South San Francisco, CA
- Address
- 681 Gateway Boulevard, 94080 South San Francisco, United States
- Phone
- 800 719 0671
- Website
- twistbioscience.com
- IPO Date
- 10/31/2018
- ISIN
- US90184D1000
Management
| Name | Title | Birth Year |
|---|---|---|
| Emily Marine Leproust Ph.D. | Co-Founder, Board Chair & CEO | 1973 |
| Patrick John Finn Ph.D. | President & COO | 1972 |
| Adam Laponis | Chief Financial Officer | 1977 |
| Dennis Cho J.D. | Chief Legal Officer & Corporate Secretary | 1971 |
| Paula Green | Senior Vice President of Human Resources | 1968 |
| Robert F. Werner | VP & Chief Accounting Officer | 1973 |
| Siyuan Chen | Chief Technology Officer | – |
| Michael Fero Ph.D. | Chief Information Officer | – |
| Colby Souders Ph.D. | Chief Scientific Officer | – |
| Nicole Moreno | Senior Vice President of Sales & Support | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
- 08/19/2026 Twist Bioscience Corp (TWST): Other Events; Financial Statements and Exhibits SEC ↗
- 08/18/2026 Twist Bioscience Corp (TWST): Regulation FD Disclosure SEC ↗
- 08/05/2026 Twist Bioscience Corp (TWST): Entry into a Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibits SEC ↗
- 08/03/2026 Twist Bioscience Corp (TWST): Results of Operations and Financial Condition; Financial Statements and Exhibits SEC ↗
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.